UBS Group’s Reviva Pharmaceuticals RVPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $76 | Sell |
200
-223,341
| -100% | -$84.9K | ﹤0.01% | 8698 |
|
|
2025
Q1 | $213K | Buy |
+223,541
| New | +$213K | ﹤0.01% | 5274 |
|
|
2024
Q4 | – | Sell |
-2,313
| Closed | -$3.33K | – | 8987 |
|
|
2024
Q3 | $3.33K | Sell |
2,313
-130,127
| -98% | -$187K | ﹤0.01% | 7072 |
|
|
2024
Q2 | $170K | Buy |
132,440
+124,341
| +1,535% | +$159K | ﹤0.01% | 4658 |
|
|
2024
Q1 | $30.6K | Buy |
+8,099
| New | +$30.6K | ﹤0.01% | 5566 |
|
|
2022
Q1 | – | Sell |
-1,964
| Closed | -$6K | – | 9548 |
|
|
2021
Q4 | $6K | Buy |
1,964
+386
| +24% | +$1.18K | ﹤0.01% | 8167 |
|
|
2021
Q3 | $6K | Sell |
1,578
-455
| -22% | -$1.73K | ﹤0.01% | 7290 |
|
|
2021
Q2 | $10K | Buy |
+2,033
| New | +$10K | ﹤0.01% | 6956 |
|
|
2021
Q1 | – | Sell |
-1,710
| Closed | -$15K | – | 8180 |
|
|
2020
Q4 | $15K | Buy |
1,710
+1,682
| +6,007% | +$14.8K | ﹤0.01% | 6152 |
|
|
2020
Q3 | $0 | Sell |
28
-454
| -94% | – | ﹤0.01% | 7346 |
|
|
2020
Q2 | $5K | Buy |
482
+35
| +8% | +$363 | ﹤0.01% | 6523 |
|
|
2020
Q1 | $5K | Sell |
447
-1,900
| -81% | -$21.3K | ﹤0.01% | 6395 |
|
|
2019
Q4 | $25K | Hold |
2,347
| – | – | ﹤0.01% | 5690 |
|
|
2019
Q3 | $24K | Buy |
2,347
+1,247
| +113% | +$12.8K | ﹤0.01% | 5673 |
|
|
2019
Q2 | $11K | Hold |
1,100
| – | – | ﹤0.01% | 6144 |
|
|
2019
Q1 | $11K | Buy |
+1,100
| New | +$11K | ﹤0.01% | 5919 |
|